The Asia-Pacific region is seeing rapid growth in oncology drug research, with a 138 percent increase in clinical trial activity from 2010 to 2020, according to a recent Clinical Trials Arena report. The APAC region now ranks first in the world for the number of ongoing oncology clinical trials, accounting for more than half of those studies. Large populations, a favorable regulatory climate, and a high incidence of cancer are among the many reasons sponsors are drawn to the region.
In this webinar, we will examine the advantages of conducting trials in this fast-growing region and explore other issues sponsors should consider when choosing sites for upcoming trials.
- Patient access
- Cost advantages
- Regulatory landscape
Key Learning Objectives:
- Recognize the advantages of the patient population in APAC
- Understand the APAC regulatory landscape
- Learn how APAC is positioned to adopt new technologies
Rupa Doshi, Ph.D.
Vice President, Oncology Strategy, Premier Research
Senior Vice President, Asia-Pacific, Premier Research